Fig. 3From: Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature reviewOverall survival (OS) at 1Â year and 2Â years as reported in trials of Gliadel wafers combined with standard radiotherapy (RT) and concurrent followed by adjuvant temozolomide (TMZ) for the treatment of high-grade glioma. The 1-year and 2-year OS values of these trials are compared with the values for the active treatment arm of the 240-patient phase III clinical trial of Gliadel wafers plus RT [8, 10] (column 1) and the active treatment arm of the phase III clinical trial of RT/TMZ (column 2) [11, 12]Back to article page